Bayer’s “Next Wave” Of Products Will Reach Phase III Beachhead By 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview, Bayer HealthCare’s recently-arrived new chief executive Olivier Brandicourt discusses the five assets that most excite the firm.
You may also be interested in...
Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets
Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.